EGETIS THERAPEUTICS AB |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.69 SEK | -2.90% |
|
-27.20% | +2.15% |
| 06-20 | Transcript : Egetis Therapeutics AB - Special Call | |
| 06-19 | Egetis Therapeutics AB Announces Topline Results of the Phase 2 Triac Trial II with Emcitate for MCT8 Deficiency | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Compared values
| Sector | Change | 5d. change | 1st Jan change | 1-year change | 5-years change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| EGETIS THERAPEUTICS AB | Bio Therapeutic Drugs | -2.90% | -27.20% | +2.15% | +23.91% | -69.19% | 163M |  |  |  |
Technical Rankings Surperformance
- Stock Market
- Equities
- EGTX Stock
- Charts Egetis Therapeutics AB
- Comparison Chart
